^
Association details:
Biomarker:No biomarker
Cancer:Ovarian Cancer
Drug:Mvasi (bevacizumab-awwb) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
01/15/2018
Excerpt:
Mvasi,....in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents....in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
Secondary therapy:
pegylated liposomal doxorubicin; carboplatin + bisphosphonate bound paclitaxel; carboplatin + gemcitabine; topotecan